Mice bearing human primary pre-B ALL xenografts: CTL019 improved survival vs mock T cells
“A series of studies in mice bearing human primary pre-B ALL conducted to evaluate anti-tumor activity of CTL019 derived from different healthy human donors showed significantly improved survival in the tumor-bearing mice receiving intravenous (i.v.) injection of CTL019 at 2x106 cells/mouse as compared to the mock T cell administered animals.”
✓ VerifiedFDA pharmacology/toxicology review, p. 2Source ↗
Why that model
Patient-specific human T-cell product cannot be given to immunocompetent animals; xenograft in immunodeficient mice used
“The lack of single-dose toxicity studies is acceptable, since tisagenlecleucel is a patient specific product, which is not appropriate to administer to immune competent animals.”
autologous cultured chondrocytes on porcine collagen membrane · Autologous chondrocytes
Analogous MACI (animal cells on same membrane) in critical-sized knee/stifle cartilage defects in rabbits and horses: improved repair vs membrane alone or empty defect